Optimi Health Corp (CSE:OPTI, OTCQB:OPTHF, FRA:8BN). (CSE:OPTI) (OTCQB:OPTHF) (FRA: 8BN) Chairman JJ Wilson tells Proactive the Vancouver-Canada based group is positioning itself to be a significant player in the natural psilocybin space.
Wilson says the group is working with IMPACT Clinical Trials Accelerator at the University of Calgary to begin a Phase 1 clinical trial to develop natural formulations of psilocybin to treat anxiety, depression, and alcoholism.